Improvement in the Selection of Patients for Anti-PD1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) Analyzing Tumor Mutational Burden and Retrotransposon Activity as Possible New Biomarker of Effectiveness
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.